# Theraclion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/theraclion

- Industry: Medical Devices & Equipment
- Headquarters: Malakoff, France
- Website: www.theraclion.com
- Total disclosed funding: $11M
- Latest round: Series C (Mar 30, 2012)
- Investors on record: 2

## About

Theraclion is a French medical technology company that develops innovative echotherapy systems for non-invasive treatments, primarily focusing on varicose veins and other conditions using High-Intensity Focused Ultrasound.Theraclion, headquartered in Malakoff, France, specializes in the development of echotherapy technologies. The company has pivoted towards non-invasive treatments, particularly with its flagship products SONOVEIN® and ECHOPULSE®. The company has raised a total of EUR 0.25 mn, with the most recent funding round being a Series C in March 2012, where it secured EUR 1.6 mn from new investor Karista and returning investor Truffle Capital. CEO Martin Deterre leads the organization.Theraclion specializes in developing non-invasive echotherapy technologies, focusing on SONOVEIN® and ECHOPULSE®. SONOVEIN® offers a robotic system for non-surgical treatment of varicose veins through High-Intensity Focused Ultrasound (HIFU). The advanced SONOVEIN® HD incorporates superior imaging, enhancing its effectiveness. ECHOPULSE® allows for non-invasive treatment of thyroid nodules and breast fibroadenomas, preserving surrounding tissue integrity. These technologies are marketed globally, especially in Europe and the United States, targeting healthcare providers seeking alternatives to traditional surgical methods.In the most recent fiscal year, Theraclion reported a revenue of EUR 1,608,485.50. The company's revenue model is based on the direct sales of its echotherapy systems, including SONOVEIN® and ECHOPULSE®, and associated services. Theraclion builds long-term partnerships with healthcare institutions, facilitating the integration of its technologies into their treatment offerings.Theraclion aims to expand its product portfolio with upcoming developments in echotherapy technologies. The company is strategically targeting new markets, including various regions in Europe and the United States, with plans for broader market penetration by 2025. The recent funding of EUR 1.6 mn raised in March 2012 will support these initiatives, enabling the company to enhance its product offerings and expand into new geographic areas.

## Funding rounds

- Series C, Mar 30, 2012, $2.1M — Truffle Capital, Karista
- Series C, Feb 2, 2011, $2.7M — Truffle Capital
- Series C, Dec 29, 2008, $2.7M — Truffle Capital
- Series C, Jul 6, 2005, $3M — Truffle Capital

## Investors

- Truffle Capital (https://capitalatlas.ai/funds/truffle-capital) — Series C
- Karista (https://capitalatlas.ai/funds/karista) — Series C